Nathwani A C, Davidoff A M, Tuddenham E G D
Department of Haematology, University College London, 98 Chenies Mews, London, WC1E 6HX, UK.
Haemophilia. 2004 Jul;10(4):309-18. doi: 10.1111/j.1365-2516.2004.00926.x.
That gene therapy offers the promise of a cure for haemophilia was apparent more than a decade ago. After years of failure, substantial progress in the efficiency of gene transfer technology has recently resulted in impressive success in animal models with haemophilia. However, fears of the risks intrinsic to such therapy have been raised by the fate of two children cured of immune deficiency by gene transfer who have, however, subsequently developed leukaemia as a result of insertional mutagenesis. The purpose of this review is to outline the current status of gene therapy in light of recent successes and tragedies and to consider the prospects for curing haemophilia in the short-to-medium term.
十多年前,基因疗法有望治愈血友病这一点就已很明显。历经数年失败后,基因转移技术效率取得了实质性进展,最近在血友病动物模型中取得了令人瞩目的成功。然而,通过基因转移治愈免疫缺陷的两名儿童后来因插入诱变患上白血病,这引发了人们对这种疗法固有风险的担忧。本综述的目的是根据近期的成功与悲剧概述基因疗法的现状,并探讨在中短期内治愈血友病的前景。